HIV & AIDS

Naltrexone implant helps HIV patients prevent opioid relapse

(HealthDay)—Slow-release implantable naltrexone is associated with better outcomes than the oral drug for HIV-positive patients with an opioid addiction, according to a study published in the April issue of The Lancet HIV.

HIV & AIDS

In rare cases, immune system fails despite HIV suppression

Antiretroviral therapy (ART) is usually very effective at suppressing HIV in the body, allowing a person's immune system to recover by preventing the virus from destroying CD4+ T cells. Scientists have now identified a rare, ...

HIV & AIDS

Novel antibody may suppress HIV for up to four months

Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) ...

HIV & AIDS

Privacy concerns keep men from HIV testing, treatment

Privacy concerns linked to both health facilities and providers are major barriers to increasing the number of men who are tested and treated for HIV in Cote d'Ivoire, suggests new Johns Hopkins Center for Communication Programs ...

HIV & AIDS

CDC: New HIV transmission often from those unaware of infection

(HealthDay)—Most new HIV transmissions are from people who do not know they have HIV infection or are aware of infection but are not receiving care, according to research published in the March 18 early-release issue of ...

HIV & AIDS

'Highly significant' results of HIV transmission study released

Positive results from a University of Liverpool led research project that aims to reduce mother to child transmission of HIV have been presented at the Annual international Conference on Retroviruses and Opportunistic Infections ...

Health

Long-acting regimen noninferior to daily ART for HIV-1

(HealthDay)—Monthly long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) are noninferior to daily regimens for patients with HIV-1, according to two studies presented at the Conference on Retroviruses and Opportunistic ...

page 1 from 23